ArticleThe Journal of clinical endocrinology and metabolism2021
Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling.
Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Agreement Between Molecular Imaging and Adrenal Vein Sampling for Localization in Primary Aldosteronism: A Systematic Review.Journal of the American Heart Association · 2026Pooled it
- A Ten Year Overview of Adrenal Vein Sampling in Croatia: Insights and Outcomes.Clinical endocrinology · 2026Article
- When "right" goes wrong: poor accuracy of calculated right adrenal vein aldosterone levels in subtyping primary aldosteronism.CVIR endovascular · 2026Article
- Molecular pathology of primary aldosteronism and hypercortisolism: Impact on adrenal surgery.iScience · 2026Review
- Primary Hyperaldosteronism: Epidemiology, Diagnosis, and Clinical Associations.Epidemiologia (Basel, Switzerland) · 2026Review
- Approach to the Patient With Primary Aldosteronism: Role of Molecular Imaging.The Journal of clinical endocrinology and metabolism · 2025Review
- Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism.BMC endocrine disorders · 2025Article
- Intraprotocol Adrenal Vein Sampling Inconsistencies in Primary Aldosteronism Lateralization.Radiology · 2025Article
- Resolution of paradoxical bilateral aldosterone suppression with mass spectrometry.European journal of endocrinology · 2025Article
- Primary aldosteronism: adrenalectomy could save more lives.Frontiers in endocrinology · 2025Review
- [Diagnostics (Basel, Switzerland) · 2024Article
- Utility of Adrenal Vein Sampling With and Without Ultra-Low Dose ACTH Infusion in the Diagnostic Evaluation of Primary Aldosteronism.Endocrinology, diabetes & metabolism · 2024Article
- Successful Superficial Blood Sampling to Localize a Fibroblast Growth Factor-23-Producing Tumor.The American journal of case reports · 2024Article
- The value of plasma metanephrine measurements during adrenal vein sampling.Endocrine connections · 2024Article
- Autoimmune Implications in a Patient with Graves' Hyperthyroidism, Pre-eclampsia with Severe Features, and Primary Aldosteronism.Medicina (Kaunas, Lithuania) · 2024Article
- Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Endocrine reviews · 2024Article
- A clinical assessment of portable point-of-care testing for quick cortisol assay during adrenal vein sampling.Scientific reports · 2023Observational
- Application of a Radiomics Machine Learning Model for Differentiating Aldosterone-Producing Adenoma from Non-Functioning Adrenal Adenoma.Bioengineering (Basel, Switzerland) · 2023Article
- 18-Oxocortisol: A journey.The Journal of steroid biochemistry and molecular biology · 2023Article
- Aldosterone- and Cortisol Co-secreting Adrenal Cortical Neoplasm With Lipomatous and Myelolipomatous Metaplasia .JCEM case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Several studies over the past 3 decades document a higher prevalence of primary aldosteronism (PA) among hypertensive patients than generally presumed. PA exists as a spectrum from mild to severe aldosterone excess. Although a variety of PA subtypes exist, the 2 most common are aldosterone-producing adenomas (APAs) and bilateral hyperaldosteronism (BHA). The distinction is important, because APA-and other subtypes, with aldosterone production mostly from 1 adrenal-can be cured surgically, and BHA should be treated medically with mineralocorticoid-receptor antagonists (MRAs). The major shortcomings in the tailored management of patients with possible PA are the low rates of screening for case identification and the expensive and technically challenging imaging and interventional procedures required to distinguish APA from BHA, especially adrenal vein sampling (AVS). When AVS identifies an APA and allows the patient to be cured surgically, the procedure is of great value. In contrast, the patient with BHA is treated with MRA whether AVS is performed or not. Consequently, it is prudent to gauge how likely it is to benefit from imaging and AVS in each case prior to embarking on these studies. The explosion of information about PA in the past decade, including predictors of APA and of surgical benefit, are useful in limiting the evaluation for some patients with a positive PA screening test. This article will review our suggestions for approaching these patients in a pragmatic style, recognizing the limitations to even the best resources and facilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.